218 related articles for article (PubMed ID: 1995531)
1. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
Brown JM; Lemmon MJ
Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
[TBL] [Abstract][Full Text] [Related]
2. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
3. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
[TBL] [Abstract][Full Text] [Related]
4. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
Zeman EM; Lemmon MJ; Brown JM
Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
[TBL] [Abstract][Full Text] [Related]
5. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
6. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
Stern S; Guichard M
Radiother Oncol; 1996 Nov; 41(2):143-9. PubMed ID: 9004358
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
Zeman EM; Hirst VK; Lemmon MJ; Brown JM
Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
[TBL] [Abstract][Full Text] [Related]
10. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
Xu P; Huang JM; Ren Y; Zha X; Deng BF; Wu JH; Lang JY
Chin J Cancer; 2010 Feb; 29(2):126-30. PubMed ID: 20109337
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
Minchinton AI; Brown JM
Br J Cancer; 1992 Dec; 66(6):1053-8. PubMed ID: 1457345
[TBL] [Abstract][Full Text] [Related]
12. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
[TBL] [Abstract][Full Text] [Related]
13. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
Zhang M; Stevens G
Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
[TBL] [Abstract][Full Text] [Related]
14. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
15. Reoxygenation and rehypoxiation in the SCCVII mouse tumor.
Kim IH; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):493-7. PubMed ID: 8005805
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targets in radiotherapy.
Brown JM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):319-26. PubMed ID: 11173124
[TBL] [Abstract][Full Text] [Related]
17. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
Minchinton AI; Lemmon MJ; Tracy M; Pollart DJ; Martinez AP; Tosto LM; Brown JM
Int J Radiat Oncol Biol Phys; 1992; 22(4):701-5. PubMed ID: 1544841
[TBL] [Abstract][Full Text] [Related]
18. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
Lambin P; Guichard M; Chavaudra N; Malaise EP
Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
el-Said A; Menke D; Dorie MJ; Brown JM
Radiat Oncol Investig; 1999; 7(3):163-9. PubMed ID: 10406058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
